Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]
Discontinued
Reference number: GID-TA10569
Following on from information provided to NICE by the company in February 2021, the appraisal of Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.